PRINCETON, N.J., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that five posters across its development programs will be included at the Society for the Study of Inborn Errors of Metabolism (SSIEM) 2024 Annual Symposium, being held September 3-6, 2024 in Porto, Portugal.

Poster Sessions:

Fabry Disease:

Abstract Title: FollowME Fabry Pathfinders registry: patient-reported outcomes in a cohort of patients on migalastat treatment for at least two years (Poster #21180)

• Presenter: Aleš Linhart, D.Sc., Charles University and General University Hospital in Prague, Prague, Czech Republic
• Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
• Location: Poster Room, Rosa Mota Pavilion
  

Abstract Title: Quality of life of migalastat-treated adolescents with Fabry disease: results from the ASPIRE study and open-label extension (Poster #21202)

• Presenter: Amarilis Sanchez-Valle, MD, University of South Florida Health, Tampa, U.S.A.
• Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
• Location: Poster Room, Rosa Mota Pavilion
  

Abstract Title: Exploring the journey of patients living with Fabry disease in Poland (Poster #20789)

• Presenter: Anna Moskal, The Association of Families with Fabry Disease, Wroclaw, Poland
• Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
• Location: Poster Room, Rosa Mota Pavilion
  

Pompe Disease:

Abstract Title: Post-baseline outcomes of the UK Early Access to Medicines Scheme registry for cipaglucosidase alfa plus miglustat in late-onset Pompe disease (Poster #20863)

• Presenter: Elaine Murphy, MD, University College London Hospitals, London, U.K.
• Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
• Guided Poster Walk: Thursday, September 5, 12:10 – 1:40 p.m. WET
• Location: Poster Room, Rosa Mota Pavilion

Abstract Title: Miglustat: a first-in-class enzyme stabilizer for late-onset Pompe disease (Poster #20873)

• Presenter: Mark Roberts, MD, Salford Royal NHS Foundation Trust, Greater Manchester Neurosciences Centre, Manchester, U.K.
• Poster Session: Wednesday, September 4, 6:15 – 8:15 p.m. WET
• Location: Poster Room, Rosa Mota Pavilion
  

For more information on the SSIEM 2024 Annual Symposium, please visit ssiem2024.org.

About Amicus Therapeutics
Amicus Therapeutics (Nasdaq: FOLD) is a global, patient-dedicated biotechnology company focused on discovering, developing and delivering novel high-quality medicines for people living with rare diseases. With extraordinary patient focus, Amicus Therapeutics is committed to advancing and expanding a pipeline of cutting-edge, first- or best-in-class medicines for rare diseases. For more information please visit the company’s website at www.amicusrx.com, and follow on X and LinkedIn.

CONTACTS:

Investors:
Amicus Therapeutics
Andrew Faughnan
Vice President, Investor Relations
afaughnan@amicusrx.com
(609) 662-3809

Media:
Amicus Therapeutics
Diana Moore
Head of Global Corporate Communications
dmoore@amicusrx.com
(609) 662-5079

FOLD–G